Trial data showed Ocrevus treatment slowed disability progression in PPMS, including patients who were older and had more ...

Columnist Ben Hofmeister reflects on the feelings of guilt that surfaced after writing that his present vehicle no longer met his needs.

Guest writer Kevin Byrne explains "Garage Dayz," his ambitious cycling project dedicated to fellow members of the MS ...

The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...

Scientists studying animals at high altitudes discovered a previously unknown mechanism that is key for regulating myelin ...

Columnist Desiree Lama is reconnecting with her love of plants and being outside after starting an outdoor garden at her new ...

Medicaid coverage of highly effective disease-modifying therapies for MS varies widely across the U.S., with no coverage in ...

Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.

A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...

Guest columnist Lindsay Kelly says that receiving her husband Rhead's MS diagnosis gave her a helpful framework for ...

Real-world use of an MS blood test shows how it helps monitor disease activity and guide treatment decisions in U.S. patients ...

Long-term treatment with Ocrevus preserved hand and walking function for people with early active relapsing-remitting MS, a ...